Liver Cancer

Liver Cancer Screening Awareness

Understanding who needs liver cancer surveillance, which tests are used, and how early detection changes outcomes.

Liver cancer — primarily hepatocellular carcinoma (HCC) — is among the few cancers where a clearly defined high-risk population exists and routine surveillance has been shown to improve outcomes. Unlike many cancers where population-wide screening is debated, liver cancer surveillance is recommended for a specific group: adults with established liver cirrhosis, and certain others with chronic hepatitis B infection. For those in these groups, the question is not whether to screen but how consistently to do it.

Despite this, surveillance rates remain well below recommended levels. Studies suggest that fewer than one in five eligible adults with cirrhosis receive the recommended semi-annual ultrasound. The gap between who should be screened and who actually is screened remains one of the most significant barriers to improving liver cancer survival in the United States.

This article explains who qualifies for surveillance, what the standard protocol involves, and what current evidence says about additional tools — including alpha-fetoprotein (AFP) testing and emerging biomarker panels — that may improve early detection rates.

Who Is Considered High-Risk for Liver Cancer?

Liver cancer does not arise randomly. In approximately 90% of cases, it develops in a liver that has already been damaged by a chronic underlying condition. The most common risk factors include:

• Liver cirrhosis from any cause: Cirrhosis — scarring of the liver tissue from chronic injury — is the single largest risk factor for HCC, regardless of what caused the cirrhosis. Alcohol-related liver disease, nonalcoholic steatohepatitis (NASH), chronic hepatitis C, autoimmune hepatitis, hereditary hemochromatosis, primary biliary cholangitis, and alpha-1 antitrypsin deficiency can all lead to cirrhosis and increased HCC risk. Any adult with confirmed cirrhosis is considered high-risk for surveillance purposes.
• Chronic hepatitis B without cirrhosis: Unlike most other liver diseases, hepatitis B virus (HBV) can cause HCC even in the absence of cirrhosis. The virus integrates directly into the genome and can drive malignant transformation independently of fibrosis. The threshold for surveillance in HBV-infected adults without cirrhosis is guided by age, ethnicity, family history, and HBV activity. Asian men over 40, Asian women over 50, Africans over 20, and any HBV carrier with a family history of HCC are generally recommended for ongoing surveillance.
• Chronic hepatitis C without cirrhosis: Hepatitis C infection without cirrhosis carries elevated but lower HCC risk than HBV without cirrhosis. Current major guidelines do not uniformly recommend HCC surveillance for non-cirrhotic HCV patients, though patients who have achieved sustained virologic response (SVR) after antiviral therapy retain some residual risk, particularly if significant fibrosis (stage F3) was present before treatment.
• Nonalcoholic fatty liver disease (NAFLD/NASH): NASH is the fastest-growing cause of cirrhosis and liver-related mortality in developed countries, and by extension a growing contributor to HCC risk. Surveillance guidelines are clearest for NASH patients who have progressed to cirrhosis. HCC in NASH can occur without cirrhosis, though this is less common and guidelines remain less definitive about surveillance in non-cirrhotic NASH.

If you have any of these conditions, discuss liver cancer surveillance with your gastroenterologist or hepatologist. A related resource on the broader landscape of digestive and liver health is our article on digestive health after age 60.

The Standard Surveillance Protocol: Ultrasound Every Six Months

Current guidelines from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) recommend abdominal ultrasound every six months as the cornerstone of HCC surveillance for high-risk adults. This interval is based on the estimated doubling time of HCC tumours — the six-month schedule is designed to detect tumours while they are still within the size range where curative treatment remains possible.

What the ultrasound detects: Abdominal ultrasound for HCC surveillance looks for liver nodules — focal abnormalities within the liver parenchyma. In a patient with cirrhosis, any new nodule ≥1 cm warrants further characterisation with cross-sectional imaging (typically a four-phase CT or MRI with contrast), which can often diagnose HCC non-invasively based on characteristic enhancement patterns, without biopsy. Nodules smaller than 1 cm are typically followed with repeat ultrasound at three-month intervals rather than immediate further workup.

Limitations of ultrasound: Ultrasound sensitivity for early HCC detection is moderate — pooled estimates from meta-analyses suggest sensitivity of approximately 63–65% for early-stage tumours. Obesity, significant ascites, and advanced cirrhosis with heterogeneous liver parenchyma all reduce ultrasound sensitivity. This has driven research into whether adding AFP testing to ultrasound improves early detection, which is discussed below.

Who performs the surveillance: Surveillance ultrasounds are typically ordered and reviewed by gastroenterologists, hepatologists, or gastroenterology nurse practitioners as part of a structured cirrhosis care programme. The interpreting radiologist should have familiarity with the LI-RADS (Liver Imaging Reporting and Data System) framework, which provides standardised terminology for reporting liver observations in patients at risk for HCC.

Alpha-Fetoprotein (AFP): Role in Surveillance and Limitations

Alpha-fetoprotein is a protein produced in elevated amounts by many HCC tumours. Blood AFP measurement has been studied as a surveillance tool for decades, and its role remains nuanced and debated:

Current guideline position: Earlier versions of major guidelines recommended AFP as a surveillance tool alongside ultrasound. More recent AASLD guidance moved away from recommending routine AFP addition to ultrasound in biannual surveillance, primarily because AFP lacks sufficient sensitivity (many early HCCs do not produce detectable AFP elevation) and specificity (AFP is elevated in other liver conditions, particularly active hepatitis and cirrhosis, leading to false-positive results that trigger unnecessary further workup). EASL guidelines have similarly moved toward ultrasound-alone as the primary surveillance modality.

The case for AFP addition: Several studies and centres continue to use AFP alongside ultrasound, arguing that the combination improves sensitivity over ultrasound alone (combined sensitivity approximately 63–87% depending on the study and AFP threshold used). The HALT-C trial and subsequent analyses suggested that surveillance ultrasound plus AFP was significantly more likely to detect early-stage HCC than ultrasound alone in some populations. The trade-off is increased false-positive rates and additional workup costs.

AFP-L3 and DCP: Two modified AFP assays — AFP-L3 fraction (which measures the proportion of AFP with altered glycosylation associated with HCC) and des-gamma-carboxyprothrombin (DCP, also called PIVKA-II) — are more specific to HCC than total AFP and are used in some clinical settings, particularly in Japan and Korea, where HCC surveillance is more extensively implemented. These tests are available in the US but not yet standard in most surveillance programmes.

Emerging Approaches: Liquid Biopsy and Biomarker Panels

The recognised limitations of ultrasound sensitivity for early HCC, particularly in obese patients and those with advanced cirrhosis, have driven significant research into blood-based biomarker approaches:

Circulating tumour DNA (ctDNA): HCC tumour cells shed fragments of tumour-specific DNA into the bloodstream. Assays detecting methylation patterns or specific mutations in circulating cell-free DNA have shown promising sensitivity for early HCC in research settings. However, ctDNA-based HCC detection tests are not yet validated for clinical use and remain investigational.

GALAD score: The GALAD score combines gender, age, AFP-L3, AFP, and DCP into a single score that has shown improved sensitivity and specificity for HCC detection compared to any single marker alone. It has been validated in multiple cohorts and is used in some specialist hepatology centres in Europe and Asia. The Gastroenterology 2022 validation study reported AUROC of 0.91 for early-stage HCC detection. FDA clearance for clinical use in the US is pending further validation trials.

Abbreviated MRI protocols: Abbreviated MRI (AMRI) — a shortened hepatobiliary MRI protocol taking 15–20 minutes rather than 45–60 — has shown substantially better sensitivity for early HCC than ultrasound (approximately 80% vs. 47% in direct comparison studies) with acceptable specificity. Several gastroenterology societies now recommend AMRI as a surveillance alternative for patients in whom ultrasound is likely to be inadequate (primarily those with obesity or advanced cirrhosis). The barrier to widespread AMRI adoption is cost and MRI capacity availability.

Why Surveillance Gaps Persist and How to Address Them

Even in patients who have been told they need surveillance, multiple factors contribute to surveillance gaps — the failure to complete recommended semi-annual ultrasounds on schedule:

• Lack of a structured recall system: In many healthcare settings, the responsibility for scheduling the next surveillance ultrasound falls to the patient after a verbal instruction. Without an automated recall system or standing order, patients are at risk of allowing the surveillance interval to lapse. Specialist hepatology clinics with structured recall programmes have substantially higher surveillance adherence rates than general primary care settings.
• Asymptomatic nature of early HCC: Liver cancer in its earliest, most treatable stages causes no symptoms. Patients who feel well may deprioritise a preventive test that seems distant from any current problem. Education that emphasises the long window of treatability for early-stage tumours can help motivate adherence.
• Limited access to hepatology specialists: Patients with cirrhosis managed entirely in primary care settings are less likely to receive guideline-concordant HCC surveillance than those with access to specialist care. Telemedicine-based hepatology services have improved this in some regions, but access disparities persist.
• Competing health priorities: For patients managing cirrhosis alongside other chronic conditions — type 2 diabetes, cardiovascular disease, kidney disease — HCC surveillance may not always be the most salient health appointment. Integrating surveillance into a broader liver disease management framework, rather than treating it as a standalone test, can help patients understand its place in their overall care plan.

For those managing related digestive conditions alongside liver health, our guide on colon cancer screening covers complementary preventive testing strategies. A broader guide to digestive supplements relevant to liver health is also available: supplements for digestive health.

What Happens After an Abnormal Surveillance Result

Receiving an abnormal ultrasound result — typically the identification of a new liver nodule — does not mean a liver cancer diagnosis. The next steps follow a structured pathway based on nodule size and imaging characteristics:

Nodule <1 cm: Repeat surveillance ultrasound at three-month intervals. Most sub-centimetre nodules in cirrhotic patients are not malignant, but short-interval follow-up is required to catch any that grow into the actionable size range.

Nodule 1–2 cm: Cross-sectional imaging — typically a four-phase CT or gadoxetate-enhanced MRI — is the next step. If the nodule shows the arterial enhancement and washout pattern characteristic of HCC (LI-RADS 5 observation), it is treated as HCC without biopsy. Biopsy is reserved for cases where imaging is non-diagnostic.

Nodule >2 cm: Cross-sectional imaging, tumour board discussion, and staging workup to determine whether the tumour meets criteria for curative-intent treatment — surgical resection, liver transplantation under Milan criteria, or ablative therapy — or whether it falls into an intermediate or advanced category where systemic therapy (atezolizumab plus bevacizumab is the current first-line standard for advanced HCC) is the appropriate approach.

AFP elevation without ultrasound nodule: AFP elevation in the absence of an identified nodule is a relatively common scenario in cirrhotic patients. AFP can be elevated by active hepatitis, alcohol consumption, and other benign conditions. A single elevated AFP should be interpreted in context and typically triggers a repeat measurement after addressing any reversible causes, with further workup guided by the degree of elevation and clinical context. Markedly elevated AFP (>400 ng/mL) warrants cross-sectional imaging regardless of ultrasound findings. Related liver health information is available through the American Liver Foundation.

Frequently Asked Questions